Assure Holdings Corp. Announces Business Combination With Danam Health, Inc.
Assure Holdings Corp. Announces Business Combination With Danam Health, Inc.
Danam Health, Inc., a private pharmaceutical and healthcare services company, to merge with Assure Holdings Corp. in an all-stock transaction
私营制药和医疗保健服务公司Danam Health, Inc. 将通过全股交易与Assure Holdings Corp. 合并
DENVER, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. ("Assure") (Nasdaq: IONM) today announced that it has entered into a definitive Agreement and Plan of Merger (the "Merger Agreement") with Danam Health, Inc. ("Danam") under which Danam will merge with a newly-formed, wholly-owned subsidiary of Assure in a stock-for-stock transaction (the "Merger") in which Danam will survive as a wholly-owned subsidiary of Assure. Assure will change its name to "Danam Health Holdings Corp." and the combined company is intended to continue as a Nasdaq-listed company.
丹佛,2024年2月12日(GLOBE NEWSWIRE)——Assure Holdings Corp.(“Assure”)(纳斯达克股票代码:IONM)今天宣布,它已与达南健康公司(“达南”)签订了最终协议和合并计划(“合并协议”),根据该协议,达南将通过股票换股交易(“合并”)与Assure新成立的全资子公司合并,其中作为Assure的全资子公司,达南将得以幸存。Assure将更名为 “Danam Health Holdings Corp.”,合并后的公司打算继续作为一家在纳斯达克上市的公司。
If completed, the Merger will result in a combined company that will focus on pharmaceutical and healthcare services that will advance Danam's micro health ecosystem, and is anticipated to include a portfolio of companies with pharmacy, wholesale operations and a technology division with a novel platform for hub and clinical services.
合并完成后,合并后的公司将专注于制药和医疗保健服务,这将推进达南的微型健康生态系统,预计将包括一系列具有药房、批发业务和拥有新颖中心和临床服务平台的技术部门的公司组合。
Danam is focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. With the successful integration of its patient-centric approach and innovative healthcare applications, Danam intends to shift the dynamic of care to revolve around the patient for a wide range of therapeutic conditions. Danam offers a full spectrum of integrated solutions by leveraging the synergies of its business segments to address access, care coordination, dispensing, delivery, and clinical management of pharmaceutical products ranging from "specialty-lite" to general maintenance conditions.
Danam致力于改善患者的生活,同时为药房、提供商、药品制造商和付款人提供独特的解决方案。通过成功整合以患者为中心的方法和创新的医疗保健应用程序,Danam打算将护理动态转向以患者为中心的各种治疗疾病。Danam利用其业务部门的协同效应,提供全方位的综合解决方案,以解决从 “专科精制” 到一般维护条件的药品的获取、护理协调、配送、交付和临床管理。
"We are very excited about the merger and believe the new combined company will provide the vehicle for our future expansion," stated Suren Ajjarapu, Chairman of Danam Health. "Our mission at Danam is to empower our network of pharmacy partners and patients by providing cost savings on pharmaceutical products, automating patient centric services and overcoming inefficiencies that prevent optimal patient care. We are committed to providing manufacturers, physicians, patients and other healthcare stakeholders with technology geared to support their initiatives to attain better health outcomes."
达南健康董事长苏伦·阿贾拉普表示:“我们对合并感到非常兴奋,并相信合并后的新公司将为我们未来的扩张提供工具。”“我们在达南的使命是通过节省药品成本、自动化以患者为中心的服务以及克服阻碍最佳患者护理的效率低下问题,增强我们的药房合作伙伴和患者网络的能力。我们致力于为制造商、医生、患者和其他医疗保健利益相关者提供旨在支持他们实现更好健康结果的举措的技术。”
About the Proposed Merger:
关于拟议的合并:
The Merger is structured as a stock for stock exchange whereby all of the outstanding equity securities of Danam are to be exchanged for shares of Assure common stock. Upon completion of the proposed Merger, on a pro forma basis and based upon the number of Assure shares to be issued in the proposed Merger, current Danam stockholders are expected to own approximately 90% of the combined company and current Assure stockholders are expected to own approximately 10% of the combined company, in each case subject to certain adjustments in the Merger Agreement, and resulting in a combined publicly traded company valued in the Merger Agreement at approximately $150 million on a fully diluted basis.
合并的结构是证券交易所的股票,达南的所有已发行股权证券都将兑换成Assure普通股的股票。拟议合并完成后,根据拟议合并中将发行的Assure股份数量,目前的达南股东预计将拥有合并后公司约90%的股份,目前的Assure股东预计将拥有合并后公司约10%的股份,每种情况都需要对合并协议进行某些调整,合并协议中合并后的上市公司在全面摊薄后将达到约1.5亿美元基础。
The boards of directors of both companies have unanimously approved the Merger Agreement. The Merger is expected to close in the second quarter of 2024, subject to satisfying certain closing conditions, including the completion of certain acquisitions by Danam, a sale of assets by Assure, the receipt of shareholder approval by both companies and approval for listing of the combined company on Nasdaq.
两家公司的董事会一致批准了合并协议。合并预计将于2024年第二季度完成,但须满足某些成交条件,包括Danam完成某些收购,Assure出售资产,收到两家公司的股东批准以及合并后的公司批准在纳斯达克上市。
Upon closing of the proposed merger, Suren Ajjarapu will serve as Chairman of the combined company. The Merger Agreement provides that the Board of Directors of the combined company will comprise of five members designated by Danam.
拟议合并完成后,苏伦·阿贾拉普将担任合并后的公司的董事长。合并协议规定,合并后的公司的董事会将由Danam指定的五名成员组成。
Advisors
顾问
Joseph Gunnar & Co., LLC is serving as the exclusive financial advisor to Assure and Danam in connection with the Merger. Dorsey & Whitney LLP is serving as legal counsel for Assure and Dykema Gossett PLLC is serving as legal counsel for Danam.
Joseph Gunnar & Co., LLC担任Assure和Danam与合并有关的独家财务顾问。Dorsey & Whitney LLP担任Assure的法律顾问,Dykema Gossett PLLC担任达南的法律顾问。
About Danam
关于达南
Danam Health is a dedicated platform fostering holistic wellness. Through a blend of cutting-edge technology and compassionate care, we offer personalized solutions for mental, physical, and emotional health. Danam's experts curate innovative approaches to empower individuals on their unique wellness journeys. With a focus on integrative health, Danam aims to nurture comprehensive well-being, guiding our community towards a balanced, thriving life. For more information, visit Danam's website at .
Danam Health 是一个促进整体健康的专用平台。通过将尖端技术和富有同情心的护理相结合,我们为心理、身体和情感健康提供个性化解决方案。Danam的专家精心策划了创新的方法,让个人能够踏上独特的健康之旅。Danam专注于综合健康,旨在培育全面的福祉,引导我们的社区过上平衡、繁荣的生活。欲了解更多信息,请访问 Danam 的网站,网址为。
About Assure
关于保证
Assure Holdings Corp. is a best-in-class provider of outsourced intraoperative neuromonitoring and remote neurology services. Assure delivers a turnkey suite of clinical and operational services to support surgeons and medical facilities during invasive procedures that place the nervous system at risk including neurosurgery, spine, cardiovascular, orthopedic and ear, nose, and throat surgeries. Assure employs highly trained technologists that provide a direct point of contact in the operating room. Physicians employed through Assure subsidiaries simultaneously monitor the functional integrity of patients' neural structures throughout the procedure communicating in real-time with the surgeon and technologist. Accredited by The Joint Commission, Assure's mission is to provide exceptional surgical care and a positive patient experience. For more information, visit Assure's website at .
Assure Holdings Corp. 是外包术中神经监测和远程神经病学服务的一流提供商。Assure 提供一站式临床和手术服务,为外科医生和医疗机构在侵入性手术中提供支持,包括神经外科、脊柱、心血管、骨科以及耳鼻喉手术。Assure 雇用训练有素的技术人员,在手术室提供直接联系人。通过Assure子公司雇用的医生在整个手术过程中同时监测患者神经结构的功能完整性,并与外科医生和技术专家进行实时沟通。经联合委员会认可,Assure的使命是提供卓越的外科护理和积极的患者体验。欲了解更多信息,请访问Assure的网站,网址为。
Additional Information and Where to Find It
其他信息以及在哪里可以找到
This communication may be deemed to be solicitation material with respect to the proposed transactions between Assure and Danam. In connection with the proposed transaction, Assure intends to file relevant materials with the United States Securities and Exchange Commission, or the SEC, including a registration statement on Form S-4 that will contain a prospectus and a proxy statement. Assure will mail the proxy statement/prospectus to the Assure and Danam stockholders, and the securities may not be sold or exchanged until the registration statement becomes effective.
该通信可能被视为有关Assure和Danam之间拟议交易的招标材料。关于拟议的交易,Assure打算向美国证券交易委员会或美国证券交易委员会提交相关材料,包括一份包含招股说明书和委托书的S-4表格注册声明。Assure将把委托书/招股说明书邮寄给Assure和Danam的股东,在注册声明生效之前,不得出售或交换证券。
Investors and securityholders of Assure and Danam are urged to read these materials when they become available because they will contain important information about Assure, Danam and the proposed transactions. This communication is not a substitute for the registration statement, definitive proxy statement/prospectus or any other documents that Assure may file with the SEC or send to securityholders in connection with the proposed transactions. Investors and securityholders may obtain free copies of the documents filed with the SEC, once available, on Assure's website at , on the SEC's website at www.sec.gov or by directing a request to Assure at 7887 E. Belleview Ave., Suite 240, Denver, Colorado, USA 80111, Attention: John Farlinger, Chief Executive Officer; or by email at ir@assureiom.com.
我们敦促Assure和Danam的投资者和证券持有人在这些材料可用时阅读这些材料,因为它们将包含有关Assure、Danam和拟议交易的重要信息。 该通信不能替代Assure可能向美国证券交易委员会提交或发送给证券持有人的与拟议交易有关的注册声明、最终委托书/招股说明书或任何其他文件。投资者和证券持有人可以在Assure网站上、美国证券交易委员会网站www.sec.gov上免费获得向美国证券交易委员会提交的文件的副本,或者向位于美国科罗拉多州丹佛市东贝尔维尤大道7887号240套房80111的Assure提出申请,收件人:首席执行官约翰·法林格;或发送电子邮件至 ir@assureiom.com。
This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.
本通信不应构成卖出要约或征求出售要约或征求购买任何证券的要约,也不应在根据任何此类司法管辖区的证券法进行注册或获得资格认证之前非法的任何司法管辖区进行任何证券销售。除非通过符合经修订的1933年《证券法》第10条要求的招股说明书,否则不得发行证券。
Participants in the Solicitation
招标参与者
Each of Assure and Danam and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Assure in connection with the proposed transaction. Information about the executive officers and directors of Assure are set forth in Assure's Definitive Proxy Statement on Schedule 14A relating to the 2023 Annual Meeting of Stockholders of Assure, filed with the SEC on December 5, 2023. Other information regarding the interests of such individuals, who may be deemed to be participants in the solicitation of proxies for the stockholders of Assure will be set forth in the proxy statement/prospectus, which will be included in Assure's registration statement on Form S-4 when it is filed with the SEC. You may obtain free copies of these documents as described above.
Assure和Danam及其各自的董事和执行官均可被视为参与向Assure股东征集与拟议交易有关的代理人。有关Assure执行官和董事的信息载于Assure于2023年12月5日向美国证券交易委员会提交的与2023年Assure年度股东大会有关的附表14A的最终委托声明。有关此类个人利益的其他信息,这些个人可能被视为参与为Assure股东招募代理人,将在委托书/招股说明书中列出,委托书/招股说明书将包含在Assure向美国证券交易委员会提交的S-4表格注册声明中。如上所述,您可以免费获得这些文件的副本。
Cautionary Statements Regarding Forward-Looking Statements
关于前瞻性陈述的警示性陈述
This press release contains forward-looking statements based upon the current expectations of Assure and Danam. Forward-looking statements involve risks and uncertainties and include, but are not limited to, statements about the structure, timing and completion of the proposed transactions; the listing of the combined company on Nasdaq after the closing of the proposed merger; expectations regarding the ownership structure of the combined company after the closing of the proposed merger; the expected executive officers and directors of the combined company; the expected cash position of each of Assure and Danam and the combined company at the closing of the proposed merger; the future operations of the combined company; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: (i) the risk that the conditions to the closing of the proposed transaction are not satisfied, including the failure to timely obtain stockholder approval for the transaction, if at all; (ii) uncertainties as to the timing of the consummation of the proposed transaction and the ability of each of Assure and Danam to consummate the proposed merger, as applicable; (iii) risks related to Assure's ability to manage its operating expenses and its expenses associated with the proposed transactions pending closing; (iv) risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transactions; (v) the risk that as a result of adjustments to the exchange ratio, Assure stockholders and Danam stockholders could own more or less of the combined company than is currently anticipated; (vi) risks related to the market price of Assure's common stock; (vii) unexpected costs, charges or expenses resulting from either or both of the proposed transaction; (viii) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transactions; (ix) risks related to the inability of the combined company to obtain sufficient additional capital to continue to advance its business plan; and (x) risks associated with the possible failure to realize certain anticipated benefits of the proposed transactions, including with respect to future financial and operating results. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These and other risks and uncertainties are more fully described in periodic filings with the SEC, including the factors described in the section titled "Risk Factors" in Assure's Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the SEC, and in other filings that Assure makes and will make with the SEC in connection with the proposed transaction, including the proxy statement/prospectus described under "Additional Information and Where to Find It." You should not place undue reliance on these forward-looking statements, which are made only as of the date hereof or as of the dates indicated in the forward-looking statements. Except as required by law, Assure expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
本新闻稿包含基于Assure和Danam当前预期的前瞻性陈述。前瞻性陈述涉及风险和不确定性,包括但不限于有关拟议交易的结构、时间和完成情况的陈述;合并后的公司在拟议合并结束后在纳斯达克上市;对拟议合并后公司所有权结构的预期;合并后公司的预期执行官和董事;拟议合并结束时Assure和Danam以及合并后的公司的预期现金状况;合并后的公司的未来运营;以及其他非历史事实的陈述。由于这些风险和不确定性,实际业绩和事件发生时间可能与此类前瞻性陈述中的预期存在重大差异,其中包括但不限于:(i) 拟议交易完成条件未得到满足的风险,包括未能及时获得股东批准的交易(如果有的话);(ii)拟议交易完成的时间以及Assure和Danam双方能力的不确定性完成拟议的合并(视情况而定);(iii) 与Assure在交易完成前管理其运营费用和与拟议交易相关的开支的能力相关的风险;(iv) 与未能或延迟获得完成拟议交易所需的任何政府或准政府实体批准相关的风险;(v) 由于汇率调整,Assure股东和达南股东可能拥有比目前预期更多或更少的股份的风险;(vi) 与Assure的市场价格相关的风险普通股;(vii)因拟议交易中的一项或两项而产生的意外成本、费用或开支;(viii)拟议交易的宣布或完成可能导致的业务关系发生的不良反应或变化;(ix)与合并后的公司无法获得足够的额外资本来继续推进其业务计划相关的风险;(x)与拟议交易的某些预期收益(包括未来财务收益)可能无法实现预期收益相关的风险和经营业绩。由于这些风险和不确定性,实际结果和事件发生时间可能与此类前瞻性陈述中的预期存在重大差异。向美国证券交易委员会提交的定期文件中更全面地描述了这些风险和不确定性,包括Assure向美国证券交易委员会提交的截至2022年12月31日止年度的10-K表年度报告和截至2023年9月30日的季度10-Q表季度报告中标题为 “风险因素” 的部分中描述的因素,以及Assure就拟议交易向美国证券交易委员会提交和将要提交的其他文件,包括委托书/招股书我们在 “其他信息及在何处查找” 中进行了描述。您不应过分依赖这些前瞻性陈述,这些陈述仅在发布之日或前瞻性陈述中注明的日期作出。除非法律要求,否则Assure明确表示不承担任何义务或承诺更新或修改此处包含的任何前瞻性陈述,以反映其对前瞻性陈述的预期的任何变化或任何此类陈述所依据的事件、条件或情况的任何变化。
Contacts:
联系人:
Assure
保证
Brett Maas, Managing Principal
Hayden IR
ionm@haydenir.com
(646) 536-7331
布雷特·马斯,董事总经理
Hayden IR
ionm@haydenir.com
(646) 536-7331
Danam
达南
Danam Health Communications
Corporate: 844-251-4691
Email: investorrelations@danamhealth.com
达南健康通讯
企业:844-251-4691
电子邮件:investorrelations@danamhealth.com